Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONCORDE: DDR Inhibitors and Radiotherapy in NSCLC
NCT04550104Phase 1Recruiting
- Sponsor
- University of Leeds
- Start
- Mar 2021
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of olaparib, azd1390, ceralasertib and saruparib in non-small cell lung cancer (NSCLC) (7 arms), sponsored by University of Leeds. Primary endpoint: Dose Limiting Toxicities at 13.5 months. Started Mar 2021; status: recruiting.
02
Drugs
olaparibazd1390ceralasertibsaruparib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04550104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04550104.